ReviewInternational urology and nephrology2026
Concurrent radiosensitising regimens for bladder-preserving radiotherapy in non-metastatic muscle-invasive bladder cancer: a systematic review and structured evidence synthesis with exploratory network meta-analysis.
Review in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study.Advances in therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo synthesise randomised comparative and prospective evidence on concurrent radiosensitising regimens used with bladder-preserving radiotherapy for non-metastatic muscle-invasive bladder cancer and determine whether the available evidence supports a regimen hierarchy.
methodsPubMed/MEDLINE, Embase, Web of Science Core Collection, and Cochrane CENTRAL were searched till May 14, 2026. Randomised trials formed the comparative evidence backbone. A frequentist random-effects network meta-analysis was restricted to connected early-response data; safety, cystectomy, and long-term oncological outcomes were summarised descriptively. Prospective non-randomised and protocol-based studies were organised as an evidence map.
resultsSix randomised or randomised phase II/III trials formed the comparative evidence base. Only early response produced a connected network and no active regimen was statistically superior to radiotherapy alone. Numerical estimates were highest for radiotherapy plus paclitaxel/cisplatin (odds ratio 2.81, 95% confidence interval 0.85-9.34), followed by cisplatin-based chemoradiotherapy (1.96, 0.86-4.45); the gemcitabine-based estimate was imprecise (0.71, 0.19-2.64). The most mature randomised signal came from BC2001, in which 5-fluorouracil/mitomycin C improved locoregional control. The prospective component included 28 studies and 1690 patients; 24 studies involving 1114 patients comprised the main regimen-level map. Complete response rates ranged from 60.0% to 94.0% (median 75.6%).
conclusionConcurrent radiosensitisation is important in bladder-preserving radiotherapy, but evidence does not support a definitive cross-regimen hierarchy. Regimen selection should reflect evidence maturity, fitness, availability, toxicity, and patient preferences.
Indexed as
Identifiers
42645666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.